Frederic Chereau - 01 Mar 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc.

Reporting relationship: President and Chief Executive, Director
Issuer ticker: N/A
Reported as of: 01 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2022, 16:54:05 UTC
Next SEC filing: 17 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Andrea Paul, as Attorney-in-Fact

Key filing fact

Frederic Chereau filed Form 4 for LogicBio Therapeutics, Inc. on 03 Mar 2022.

Key facts

This page summarizes Frederic Chereau's Form 4 filing for LogicBio Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2022, 16:54.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LOGC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +328,000
Change %
Price: $0.000000
Shares after: 328,000
Date: 01 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 328,000
Exercise price: $0.7000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan.

Footnote F2

The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date.

SEC remarks

Exhibit List: Exhibit 24.1 Power of Attorney